After asset purchase from Travere, Mirum's Ctexli crosses FDA finish line in rare metabolic disorder
The approval makes chenodiol—already cleared for decades to treat radiolucent gallstones under the brand name Chenodal—the ...
A new awareness campaign from Abbott highlights a major sticking point in diabetes management: the harmful impact of societal ...
With a $430 million buyout of Australia’s Mayne Pharma locked down, Cosette Pharmaceuticals is looking to become a leading ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a prescription drug on LinkedIn.
Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...
Less than a week after newly confirmed Department of Health and Human Services (HHS) secretary Robert F. Kennedy Jr. | Less than a week after newly confirmed HHS secretary Robert F. Kennedy Jr.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback